Progesterone receptor modulators and the endometrium: Changes and consequences

Human Reproduction Update

Volumn 13, Issue 6, 2007, Pages 567-580

  Horne, Frances Mcfarland ^a   Blithe, Diana I ^b  

^a Rose Li and Associates Inc   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; ASOPRISNIL; DOXYCYCLINE; ESTRADIOL; ESTROGEN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MONOCLONAL ANTIBODY KI 67; NORETHISTERONE ACETATE; ONAPRISTONE; ORAL CONTRACEPTIVE AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; PROTEIN P100; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DENSITY; BREAST METASTASIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTRACEPTION; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSMENORRHEA; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM ATROPHY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HISTOPATHOLOGY; HORMONE RESPONSE; HUMAN; HYSTEROSCOPY; LONG TERM CARE; LOW DRUG DOSE; MENINGIOMA; MENORRHAGIA; MENSTRUAL IRREGULARITY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; UTERUS MYOMA;

DRUG AND NARCOTIC CONTROL; DRUG DESIGN; ENDOMETRIUM; FEMALE; HORMONE ANTAGONISTS; HUMANS; MENSTRUAL CYCLE; RECEPTORS, PROGESTERONE;

EID: 35548972976     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmm023     Document Type: Article

References (173)

1. Absenger Y, Hess-Stumpp H, Kreft B, Kratzschmar J, Haendler B, Schutze N, Regidor PA, Winterhager E. Cyr61, a deregulated gene in endometriosis. Mol Hum Reprod 2004;10:399-407.
2. Agostini A, Cravello L, Bretelle F, Demaisonneuve AS, Roger V, Blanc B. Risk of discovering endometrial carcinoma or atypical hyperplasia during hysteroscopic surgery in postmenopausal women. J Am Assoc Gynecol Laparosc 2001;8:533-535.
3. Al Fozan H, Al Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril 2004;82:1561-1563.
4. Alford TC, Do HM, Geelhoed GW, Tsangaris NT, Lippman ME. Steroid hormone receptors in human colon cancers. Cancer 1979;43:980-984.
5. An BS, Choi JH, Choi KC, Leung PC. Differential role of progesterone receptor isoforms in the transcriptional regulation of human gonadotropin-releasing hormone I (GnRH I) receptor, GnRH I, and GnRH II. J Clin Endocrinol Metab 2005;90:1106-1113.
6. Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, Williams RF. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception 2005; 71: 55-59.
7. Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990;97 690-694.
8. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod 2002;66:297-304.
9. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 2001;61 4576-4582.
10. Ash SJ, Farrell SA, Flowerdew G. Endometrial biopsy in DUB. J Reprod Med 1996;41:892-896.
11. Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, Palazzo J, Fiane B, Lovslett K, Burger et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-2312.
12. Baird DT, Thong KJ, Hall C, Cameron ST. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days. Hum Reprod 1995;10:2270-2276.
13. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68.
14. Bakour SH, Khan KS, Gupta JK. The risk of premalignant and malignant pathology in endometrial polyps. Acta Obstet Gynecol Scand 2000; 79:317-320.
15. Barrington JW, Bowen-Simpkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997;104 614-616.
16. Batista MC, Cartledge TP, Zellmer AW, Merino MJ, Axiotis C, Loriaux DL, Nieman LK. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: A potential new contraceptive strategy. Am J Obstet Gynecol 1992;167:60-65.
17. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Loriaux DL, Merriam GR. The antiprogestin RU486 delays the midcycle gonadotropin surge and ovulation in gonadotropin-releasing hormone-induced cycles. Fertil Steril 1994;62:28-34.
18. Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry 2002;52:386-392.
19. Ben-Arie A, Goldchmit C, Laviv Y, Levy R, Caspi B, Huszar M, Dgani R, Hagay Z. The malignant potential of endometrial polyps. Eur J Obstet Gynecol Reprod Biol 2004;115:206-210.
20. Bouchard P, Marraoui J, Massai MR, Medalie DA, DeZiegler D, Perrot-Applanat M, Frydman R, Bergeron C. Immunocytochemical localization of oestradiol and progesterone receptors in human endometrium: A tool to assess endometrial maturation. Baillieres Clin Obstet Gynaecol 1991;5:107-115.
21. Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: A potential role for the androgen receptor. Reproduction 2002;124:167-172.
22. Brenner RM, Slayden OD, Rodgers WH, Critchley HO, Carroll R, Nie XJ, Mah K. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 2003;18:1185-1193.
23. Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63-70.
24. Buckley CH, Fox H. The normal endometrium as seen in biopsy material. In: Buckley CH (ed). Biopsy Pathology of the Endometrium. London: Chapman and HallLondon, 1989, 30-47.
25. Burton KA, Henderson TA, Hillier SG, Mason JI, Habib F, Brenner RM, Critchley HO. Local levonorgestrel regulation of androgen receptor and 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrium. Hum Reprod 2003;18:2610-2617.
26. Cameron ST, Critchley HO, Buckley CH, Chard T, Kelly RW, Baird DT. The effects of post-ovulatory administration of onapristone on the development of a secretory endometrium. Hum Reprod 1996;11 40-49.
27. Cameron ST, Critchley HO, Buckley CH, Kelly RW, Baird DT. Effect of two antiprogestins (mifepristone and onapristone) on endometrial factors of potential importance for implantation. Fertil Steril 1997;67 1046-1053.
28. Cameron ST, Thong KJ, Baird DT: Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Clin Endocrinol (Oxf) 1995;43:407-414.
29. Cekan S, Aedo AR, Segersteen E, Van Look P, Messinis I, Templeton A. Levels of the antiprogestin RU 486 and its metabolites in human blood and fullicular fluid following oral administration of a single dose. Hum Reprod 1989;4:131-135.
30. Cepni I, Ocal P, Erkan S, Saricali FS, Akbas H, Demirkiran F, Idil M, Bese T. Comparison of transvaginal sonography, saline infusion sonography and hysteroscopy in the evaluation of uterine cavity pathologies. Aust N Z J Obstet Gynaecol 2005;45:30-35.
31. Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11:293-307.
32. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol 2005;192 1230-1237.
33. Chang J, Powles TJ, Ashley SE, Iveson T, Gregory RK, Dowsett M. Variation in endometrial thickening in women with amenorrhea on tamoxifen. Breast Cancer Res Treat 1998;48:81-85.
34. Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey AM, Smith SK. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 2000;15(Suppl 3):85-95.
35. Cheng KW, Cheng CK, Leung PC. Differential role of PR-A and -B isoforms in transcription regulation of human GnRH receptor gene. Mol Endocrinol 2001;15:2078-2092.
36. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-1972.
37. Chwalisz K, Brenner RM, Fuhrmann UU, Hess-Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65 741-751.
38. Chwalisz K, Elger W, Stickler T, Mattia-Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005a;20:1090-1099.
39. Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005b;26 423-438.
40. Coutifaris C, Myers ER, Guzick DS, Diamond MP, Carson SA, Legro RS, McGovern PG, Schlaff WD, Carr BR, Steinkampf MP et al. Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril 2004;82:1264-1272.
41. Crissman JD, Azoury RS, Barnes AE, Schellhas HF. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981;57 699-704.
42. Critchley HO, Brenner RM, Henderson TA, Williams K, Nayak NR, Slayden OD, Millar MR, Saunders PT. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 2001;86 1370-1378.
43. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, Buckley CH, McNeilly AS, Glasier AF. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998a;13:1218-1224.
44. Critchley HO, Wang H, Kelly RW, Gebbie AE, Glasier AF. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998b; 13:1210-1217.
45. Critchley HO, Warner P, Lee AJ, Brechin S, Guise J, Graham B. Evaluation of abnormal uterine bleeding: Comparison of three outpatient procedures within cohorts defined by age and menopausal status. Health Technol Assess 2004;8:iIi-139.
46. Croxatto HB, Kovacs L, Massai R, Resch BA, Fuentealba B, Salvatierra AM, Croxatto HD, Zalanyi S, Viski S, Krenacs L. Effects of long-term low-dose mifepristone on reproductive function in women. Hum Reprod 1998a;13:793-798.
47. Croxatto HB, Massai MR, Salvatierra AM, Fuentealba B, Croxatto HD, Lahteenmaki P. Effects of a sequential regimen of mifepristone-medroxyprogesterone, acetate on ovarian function, endometrial development and hormonal parameters. Contraception 1996;54:79-86.
48. Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993;8:201-207.
49. Croxatto HB, Salvatierra AM, Fuentealba B, Massai R. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum Reprod 1998b;13:3297-3302.
50. de Kroon CD, de Bock GH, Dieben SW, Jansen FW. Saline contrast hysterosonography in abnormal uterine bleeding: A systematic review and meta-analysis. BJOG 2003;110:938-947.
51. de Sa Rosa e Silva AC, Rosa e Silva JC, dos Reis FJ, Nogueira. AA, Ferriani RA. Routine office hysteroscopy in the investigation of infertile couples before assisted reproduction. J Reprod Med 2005;50:501-506.
52. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess-Stumpp H, Schubert G, Chwalisz K. Asoprisnil (J867): A selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68: 1019-1032.
53. DeWaay DJ, Syrop CH, Nygaard IE, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100: 3-7.
54. DeZiegler D, Fanchin R, Moustier de B, Bulletti C. The hormonal control of endometrial receptivity: Estrogen (E2) and progesterone. J Reprod Immunol 1998;39:149-166.
55. Dueholm M, Forman A, Jensen ML, Laursen H, Kracht P. Transvaginal sonography combined with saline contrast sonohysterography in evaluating the uterine cavity in premenopausal patients with abnormal uterine bleeding. Ultrasound Obstet Gynecol 2001;18:54-61.
56. Dueholm M, Lundorf E, Olesen F. Imaging techniques for evaluation of the uterine cavity and endometrium in premenopausal patients before minimally invasive surgery. Obstet Gynecol Surv 2002;57 388-403.
57. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227-233.
58. Eisinger SH, Meldrurn S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003;101 243-250.
59. Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713-723.
60. Escudero EL, Boerrigter PJ, Bennink HJ, Epifanio R, Horcajadas JA, Olivennes F, Pellicer A, Simon C. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2005;90:2081-2088.
61. Farquhar CM, Lethaby A, Sowter M, Verry J, Baranyai J. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal. menstrual bleeding. Am J Obstet Gynecol 1999;181 525-529.
62. Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003;45: 1-14.
63. Ferenczy A, Mutter G. Endometrial hyperplasia and neoplasia: Definition, diagnosis and management principles. In: Sciarra JJ,(ed). Gynecology and Obstetrics Looseleaf CD-ROM. Philadelphia. Lippincott Williams & WilkinsPhiladelphia, 2004.
64. Fernandez-Valdivia R, Mukherjee A, Mulac-Jericevic B, Conneely OM, DeMayo FJ, Amato P, Lydon JP. Revealing progesterone's role in uterine and mammary gland biology: Insights from the mouse. Semin Reprod Med 2005;23:22-37.
65. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacelogy 2006;31:628-636.
66. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417-420.
67. Garry R, Khair A, Mooney P, Stuart M. A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation. Br J Obstet Gynaecol 1996;103:339-344.
68. Gemzell-Danielsson K, van Heusden AM, Killick SR, Croxatto HB, Bouchard P, Cameron S, Bygdeman M. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002;17:2588-2593.
69. Gemzell-Danielsson K, Swahn ML, Svalander P, Bygdeman M. Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum Reprod 1993;8:870-873.
70. Gemzell-Danielsson K, Swahn ML, Westlund P, Johannisson E, Seppala M, Bygdeman M. Effect of low daily doses of mifepristone, on ovarian function and endometrial development. Hum Reprod 1997;12: 124-131.
71. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
72. Giudice LC. Genomics' role in understanding the pathogenesis of endometriosis. Semin Reprod Med 2003;21:119-124.
73. Godfrey EM, Mawson JT, Stanwood NL, Fielding SL, Schaff EA. Low-dose mifepristone for contraception: A weekly versus planned postcoital randomized pilot study. Contraception 2004;70:41-46.
74. Goldchmit F, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial pipelle sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993;82: 727-730.
75. Goldstein SR, Monteagudo A, Popiolek D, Mayberry P, Timor-Tritsch I. Evaluation of endometrial polyps. Am J Obstet Gynecol 2002;186 669-674.
76. Gravanis A, Schaison G, George M, de Brux J, Satyaswaroop PG, Baulieu EE, Robel P. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985;60:156-163.
77. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, Fritz MA, Lessey BA. Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab 2002;87:2960-2766.
78. Gronroos M, Salmi TA, Vuento MH, Jalava EA, Tyrkko JE, Maatela JI, Aromaa AR, Siegberg R, Savolainen ER, Kauraniemi TV. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer 1993;71:1279-1282.
79. Grow DR, Iromloo K. Oral contraceptives maintain a very thin endometrium before operative hysteroscopy. Fertil Steril 2006;85:204-207.
80. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, Sitruk-Ware R. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 2006;24:727-733.
81. Hall JM, McDonnell DP. Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv 2005;5 343-357.
82. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Med Pathol 2005;18:324-330.
83. Heidebrecht HJ, Buck F, Steinmann J, Sprenger R, Wacker HH, Parwaresch R. p100: A novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 1997;90 226-233.
84. Henderson TA, Saunders PT, Moffett-King A, Groome NP, Critchley HO. Steroid receptor expression in uterine natural killer cells. J Clin Endocrinol Metab 2003;88:440-449.
85. Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu EE. The effects of an antiprogesterone steroid in women: Interruption of the menstrual cycle and of early pregnancy. C R Seances Acad Sci III 1982; 294:933-938.
86. Hinckley MD, Milki AA. 1000 office-based hysteroscopies prior to in vitro fertilization: Feasibility and findings. JSLS 2004;8 103-107.
87. Ho SP, Tan KT, Pang MW, Ho TH. Endometrial hyperplasia and the risk of endometrial carcinoma. Singapore Med J 1997;38:11-15.
88. Hsu CL, Chen YL, Yeh S, Ting HJ, Hu YC, Lin H, Wang Y, Chang C. The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. J Biol Chem 2003;278:23691-23698.
89. Hunter RW, Williams KE, Buck M, Hammond IG. Metastatic small cell carcinoma of the endometrium: Prolonged remission and possible cure following chemotherapy. Int J Gynecol Cancer 1994;4:127-130.
90. Hurskainen R, Teperi J, Rissanen P, Aalto AM, Grenman S, Kivela A, Kujansuu E, Vuorma S, Yliskoski M, Paavonen J. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: Randomized trial 5-year follow-up. JAMA 2004;291:1456-1463.
91. Imaoka I, Sugimura K, Masui T, Takehara Y, Ichijo K, Naito M. Abnormal uterine cavity: Differential diagnosis with MR imaging. Magn Reson Imaging 1999;17:1445-1455.
92. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003;68:1115-1119.
93. Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet Gynecol 1986;67:670-674.
94. Johannisson E, Landgren BM, Rohr HP, Diczfalusy E. Endometrial morphology and peripheral hormone levels in women with regular menstrual cycles. Fertil Steril 1987;48:401-408.
95. Kao LC, Germeyer A, Tulac S, Lobo S, Yang JP, Taylor RN, Osteen K, Lessey BA, Giudice LC. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease-based implantation failure and infertility. Endocrinology 2003;144 2870-2881.
96. Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometnosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65:23-28.
97. Koering MJ, Healy DL, Hodgen GD. Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys. Fertil Steril 1986;45:280-287.
98. Kovacs P, Matyas S, Boda K, Kaali SG. The effect of endometrial thickness on IVF/ICSI outcome. Hum Reprod 2003;18:2337-2341.
99. Krikun G, Critchley H, Schatz F, Wan L, Caze R, Baergen RN, Lockwood CJ. Abnormal uterine bleeding during progestin-only contraception may result from f1ree radical-induced alterations in angiopoietin expression. Am J Pathol 2002;161:979-986.
100. Krikim G, Schatz F, Taylor R, Critchley HO, Rogers PA, Huang J, Lockwood CJ. Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab 2005;90 1812-1818.
101. Kurman RJ, Felix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373-379.
102. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia. in 170 patients. Cancer 1985;56:403-412.
103. Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, Nilsson CG. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998; 316:1122-1126.
104. Lebovic DI, Shifren JL, Ryan IP, Mueller MD, Korn AP, Darney PD, Taylor RN. Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum Reprod 2000;15(Suppl. 3):67-77.
105. Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum Reprod 1992;7:945-950.
106. Leslie KK, Kumar NS, Richer J, Owen G, Takimoto G, Horwitz KB, Lange C. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann N Y Acad Sci 1997;828:17-26.
107. Lessey BA. Two pathways of progesterone action in the human endometrium: implications for implantation and contraception. Steroids 2003; 68: 809-815.
108. Lessey BA, Castelbaum AJ, Wolf L, Greene W, Paulson M, Meyer WR, Fritz MA. Use of integrins to date the endometrium. Fertil Steril 2000;73: 779-787.
109. Machtinger R, Korach J, Padoa A, Fridman E, Zolti M, Segal J, Yefet Y, Goldenberg M, Ben-Baruch G. Transvaginal ultrasound and diagnostic hysteroscopy as a predictor of endometrial polyps; risk factors for premalignancy and malignancy. Int J Gynecol Cancer 2005;15 325-328.
110. Marions L, Danielsson KG, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998;70:813-816.
111. Marions L, Viski S, Danielsson KG, Resch BA, Swahn ML, Bygdeman, M, Kovacs L. Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum Reprod 1999;14:2788-2790.
112. Martineau PA, Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J Ultrasound Med 2000;19 487-489.
113. Massai MR, Pavez M, Fuentealba B, Croxatto HB, d'Arcangues C. Effect of intermittent treatment with mifepristene on bleeding patterns in Norplant implant users. Contraception 2004;70:47-54.
114. McClellan M, West NB, Brenner RM. Immunocytocheraical localization of estrogen receptors in the macaque endometrium during the luteal-follicular transition. Endocrinology 1986;119 2467-2475.
115. McDonnell DP, Chang CY, Norris JD. Development of peptide antagonists that target estrogen receptor-cofactor interactions. J Steroid Biochem Mol Biol 2000;74:327-335.
116. McGEE WB. Carcinoma of the endometrium in women under forty years of age; report of three cases. Obstet Gynecol 1958;11:388-390.
117. McGowan EM, Saad S, Bendall U, Bradstock KF, Clarke CL. Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast Cancer Res Treat 2004;83 211-220.
118. Mirkin S, Archer DF. Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in. Ishikawa cells: Implication for the endometrial effects of mifepristone. Contraception 2004; 70: 327-333.
119. Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 2002;72:163-172.
120. Mote PA, Leary JA, Avery KA, Sandelin K, Chenevix-Trench G, Kirk JA, Clarke CL, kConFab Investigators. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predommance of progesterone receptor A. Genes Chromosomes Cancer 2004;39:236-248.
121. Murphy AA, Kettel LM, Morales AJ, Roberts V, Parmley T, Yen SS. Endometrial effects of long-term low-dose administration of RU486. Fertil Steril 1995;63:761-766.
122. Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J Clin Endocrinol Metab 1993;76:513-517.
123. Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000a;190:462-469.
124. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4314.
125. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000b;85:2334-2338.
126. Myers ER, Silva S, Barnhart K, Groben PA, Richardson MS, Robboy SJ, Leppert P, Coutifaris C. Interobserver and intraobserver variability in the histological dating of the endometrium in fertile and infertile women. Fertil Steril 2004;82:1278-1282.
127. Narvekar N, Cameron S, Critchley HO, Lin S, Cheng L, Baird DT. Low-dose mifepristone inhibits endometrial proliferation and up-regulates androgen receptor. J Clin Endocrinol Metab 2004;89:2491-2497.
128. Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod 2006;21:2312-2318.
129. Newfield RS, Spitz IM, Isacson C, New MI. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin Endocrinol (Oxf) 2001;54:399-404.
130. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula. BC, Cutler GB, Merriam GR, Bardin CW, Loriaux DL. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-540.
131. Nisker JA, Ramzy I, Collins JA. Adenocarcinoma of the endoinetrium and abnormal ovarian function in young women. Am J Obstet Gynecol 1978;130:546-550,
132. Novac L, Grigore T, Cernea N, Niculescu M, Cotarcea S. Incidence of endometrial carcinoma in patients with endometrial hyperplasia. Eur J Gynaecol Oncol 2005;26:561-563.
133. Noyes RW. Uniformity of secretory endometrium. Obstet Gynecol 1956;7: 221-228.
134. Noyes RW. Endometrial development and fertility. J Miss State Med Assoc 1963;4:5-7.
135. Paulson RJ, Sauer MV, Lobo RA. Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: A hypothesis. Fertil Steril 1997;67:321-325.
136. PEPI Trial Writing Group. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The PEPI trial. JAMA 1996;275:370-375.
137. Perrault D, Eisenhauer EA, Pritchard KI, Panasci L, Norris B, Vandenberg T, Fisher B. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1996;14:2709-2712.
138. Peterson EP. Endometrial carcinoma in young women. A clinical profile. Obstel Gynecol 1968;31:702-707.
139. Pomara N, Doraiswamy PM, Tun H, Ferris S. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002;58:1436.
140. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997;57:4736-4738.
141. Rocereto TF, Saul RM, Aikins JA Jr, Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000;77:429-432.
142. Ronkin S, Northington R, Baracat E, Nunes MG, Archer DF, Constantine G, Pickar JH. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404.
143. Salamonsen LA, Kovacs GT, Findlay JK. Current concepts of the mechanisms of menstruation. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:161-179. '
144. Sampath D, Winneker RC, Zhang Z. The angiogenic factor Cyr61 is induced by the progestin R5020 and is necessary for mammary adenocarcinoma cell growth. Endocrine 2002;18:147-159.
145. Savelli L, De laco P, Santini D, Rosati F, Ghi T, Pignotti E, Bovicelli L. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol 2003;188 927-931.
146. Savoldi G, Ferrari F, Ruggeri G, Sobek L, Albertini A, Di LD. Progesterone agonists,and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines. Int J Biol Markers 1995;10:47-54. 1
147. Schubert G, Elger W, Kaufmann G, Schneider B. Reddersen G, Chwalisz K. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005;23:58-73.
148. Scully RE, Bonfiglio TA, Korman RJ, Silverberg SG, Wilkinson DS. Histological Typing of Female Genital Tract Tumours, 2nd edn. New York: Springer-Verlag, New York, 1994.
149. Shokeir TA, Shalan HM, El, Shafei MM. Significance of endometrial polyps detected hysteroscopically in eumenorrheic infertile women. J Obstet Gynaecol Res 2004;30:84-89.
150. Shushan A, Revel A, Rojansky N. How often are endometrial polyps malignant? Gynecol Obstet Invest 2004;58:212-215.
151. Shutter J, Wright TC Jr. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 2005;24: 313-318.
152. Simpson GM, El Sheshai A, Loza N, Kingsbury SJ, Fayek M, Rady A, Fawzy W. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J Clin Psychiatry 2005;66 598-602.
153. Smid-Koopman E, Kuhne LC, Hanekamp EE, Gielen SC, De Ruiter PE, Grootegoed JA, Helmerhorst TJ, Burger CW, Brinkmann AO, Huikeshoven FJ et, al. Progesterone-induced inhibition of growth and differential regulation of gene expression in PRA- and/or PRB-expressing endometrial cancer cell lines. J Sac Gynecol Investig 2005;12:285-292.
154. Smith CL, O'Malley BW. Coreglator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004; 25:45-71.
155. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber. H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril 2005;84:1719-1726.
156. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-1136.
157. Swahn ML, Bygdeman M, Cekan S, Xing S, Masironi B, Johannisson E. The effect,of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 1900; 5:402-408.
158. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dosiou C, Le Shay N, Nezhat CN, Kempson R, Lessey BA et al. Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovulatory women. Endocrinology 2006;147:1097-1121.
159. Valenzuela P, Sanz JM, Keller J. Atypical endometrial hyperplasia: grounds for possible misdiagnosis of endometrial, adenocarcinoma, Gynecol Obstet Invest 2003;56:163-167.
160. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of osfemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas 2002;43:207-214.
161. von Hertzen H, Van Look PF. Antiprogestins forcontraception? Semin Reprod Med 2005;23:92-100.
162. Walker MJ, Chaudhuri PK, Beattie CW, Das Gupta TK. Steroid receptors in malignant skeletal tumors. Cancer 1980;45:3004-3007.
163. Walsh JW. Computed tomography of gynecologic neoplasms. Radiol Clin North Am 1992;30:817 - 830.
164. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006;21:295-302.
165. Westendorf JM, Rao PN, Gerace L. Cloning of cDNAs for M-phase phosphoproteins recognized by the MPM2 monoclonal antibody and determination of the phosphorylated epitope. Proc Natl Acad Sci USA 1994;91:714-718.
166. Widra EA, Dunton CJ, McHugh M, Palazzo JP. Endometrial hyperplasia and the risk of carcinoma. Int J, Gynecol Cancer 1995;5:233-235.
167. Wilcox AJ, Baird DD, Weinberg CR. Time, of implantation of the conceptus and loss of pregnancy. N Engl J Med 1999;340:1796-1799.
168. Winkler B, Alvarez S, Richart RM, Crum CP. Pitfalls in the diagnosis of endometrial neoplasia. Obstet Gynecol 1984;64-185-194.
169. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711.
170. Wright TC, Holinka OF, Ferenczy A, Gatsonis CA, Mutter GL, Nicosia S, Richaft RM. Estpadiol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy. Am J Surg Pathol 2002;26 1269-1275.
171. Young AH, Gallagher P, Watson S, Del Estal D, Owen BM, Ferrier IN. I. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29:1538 - 1545.
172. Zaino RJ. Endometrial hyperplasia: Is it time for a quantum leap to a new classification? Int J Gynecol Pathol 2000;19:314-321.
173. Zeng C, Gu M, Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone. Zhonghua Fu Chan Ke Za Zhi 1998;33:490-492.